(KIWI) Speeding up a Slow Protein for Muscle Mass With Hay Kiwifruit

Overview

The specific hypothesis is that the consumption of 2 Hayward green kiwifruit (containing actinidin protease) prior to 100g of ground beef will increase the rate of protein digestion from the beef in the elderly, leading to an increased uptake of the essential amino acids. Furthermore, this increased essential amino acid availability will produce a greater postprandial net anabolic protein response, as well as increased fractional synthetic rates of muscle and liver proteins.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Other
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: November 20, 2018

Detailed Description

The specific hypothesis is that the consumption of 2 Hayward green kiwifruit (containing actinidin protease) prior to 100g of ground beef will increase the rate of protein digestion from the beef in the elderly, leading to an increased uptake of the essential amino acids. Furthermore, this increased essential amino acid availability will produce a greater postprandial net anabolic protein response, as well as increased fractional synthetic rates of muscle and liver proteins.

To test this hypothesis, the investigators will use a double-blinded crossover design involving two intervention arms; in both arms 100g of ground beef (cooked weight) will be consumed following either 2 Hayward green kiwifruit (containing actinidin protease) or 2 Hort16A Gold kiwifruit (devoid of actinidin protease) by elderly subjects.

Interventions

  • Other: fresh kiwifruit
    • Subjects ate 2 peeled kiwifruit with their midday meal for 2 weeks prior to testing.

Arms, Groups and Cohorts

  • Placebo Comparator: Gold kiwifruit
    • Subjects ate 2 gold kiwifruit with midday meal for 2 weeks.
  • Active Comparator: Green Hayward kiwifruit
    • Subjects ate 2 green Hayward kiwifruit with midday meal for 2 weeks.

Clinical Trial Outcome Measures

Primary Measures

  • Whole body protein metabolism measured by Gas Chromatography-Mass Spectrometry (GC-MS)
    • Time Frame: 9.5 hours
    • Blood samples were analyzed to quantify the appearance of the stable isotopes: 2H2-tyrosine, 2H4-tyrosine, and 2H5-phenylalanine in millimoles per milliliter (mM/mL). Changes in these markers over time enable the calculation of whole body protein metabolism.

Secondary Measures

  • Skeletal muscle protein metabolism measured by Gas Chromatography-Mass Spectrometry (GC-MS)
    • Time Frame: 9.5 hours
    • Muscle samples were analyzed to quantify the appearance of the stable isotopes: 2H2-tyrosine, 2H4-tyrosine, and 2H5-phenylalanine in millimoles per milligram (mM/mg). Changes in these markers over time enable the calculation of skeletal muscle protein metabolism.

Participating in This Clinical Trial

Inclusion Criteria

  • men and women ages 60-85 inclusive.

Exclusion Criteria

  • Inability to chew meats or difficulty swallowing solid foods
  • History of diabetes
  • History of malignancy in the 6 months prior to enrolment
  • History of gastrointestinal reduction or bypass surgery (Lapband, etc)
  • History of a chronic inflammatory condition or disease (Lupus, HIV'AIDS, etc)
  • History of chronic kidney disease or currently requiring dialysis.
  • Allergy to beef or kiwifruit
  • Subjects who do not or will not eat animal proteins
  • Subjects who cannot refrain from consuming protein or amino acid supplements during their participation in this study
  • Subjects who report regular resistance exercise (more than once per week)
  • Hemoglobin less than 9.5mg/dL at the screening visit
  • Platelets less than <150,000 at the screening visit
  • Subjects who are not willing or able to suspend aspirin for several days prior to their muscle biopsies.
  • Subjects who have been prescribed a blood-thinning medication (Coumadin, lovenox, heparin, Plavix, etc).
  • Concomitant use of corticosteroids (ingestion, injection or transdermal)
  • Any other disease or condition that would place the subject at increased risk of harm if they were to participate, at the discretion of the study physician

Gender Eligibility: All

Minimum Age: 60 Years

Maximum Age: 85 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • University of Arkansas
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Arny A Ferrando, Ph.D., Principal Investigator, UAMS professor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.